A stent with a modified layer, a preparation method thereof, and an implantation device

By spraying superhydrophilic monomers onto a dense mesh stent and combining this with a dripping method to form a robust modification layer, the problem of the dense mesh stent easily inducing coagulation reactions is solved, the anticoagulation effect is improved, and the risk of thrombosis is reduced.

CN114668443BActive Publication Date: 2024-11-29成都纽创医疗器械有限公司
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202210306034.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-25
Publication Date
2024-11-29
Estimated Expiration
2042-03-25

AI Technical Summary

Technical Problem

Existing dense mesh stents are prone to causing acute coagulation reactions after implantation, leading to the risk of thrombosis and cerebral infarction, and their current anticoagulation effect is not good.

Method used

Superhydrophilic monomers are sprayed onto the scaffold matrix adsorbed onto the reactants in the transition zone under ionized conditions, and chemical grafting is performed by drop addition to form a robust modification layer, thereby improving the anticoagulation effect of the scaffold.

Benefits of technology

It significantly improved the anticoagulant properties of the stent, reduced the risk of thrombosis and cerebral ischemia, and prolonged the effective action time of the modified layer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114668443B_ABST
    Figure CN114668443B_ABST
Patent Text Reader

Abstract

The present invention discloses a stent with a modified layer, a preparation method thereof and an implant device, and belongs to the technical field of medical devices. The preparation method comprises: spraying and adsorbing a superhydrophilic monomer onto a stent substrate attached with a transition section reactant while ionizing, drying for the first time to obtain a stent primary product with a modified layer; mixing the stent primary product with a transition section reactant solution and performing a second grafting, adding the superhydrophilic monomer solution to the mixed system of the stent primary product and the transition section reactant solution by a dropwise addition method for reaction, and drying for the second time to obtain a stent with a modified layer. Compared with the existing chemical grafting process of blood flow guiding devices, the above preparation method greatly improves the firmness of the coating through the adsorption of atomic bond energy after electrolysis, and also effectively improves the hydrophilicity and biocompatibility of the product. The prepared stent product has good hydrophilicity, biocompatibility, anticoagulant property and coating firmness, and has broad application prospects in implant devices.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to a stent with a modified layer, a preparation method thereof, and an implantation device. Background Art

[0002] At present, the dense mesh stent is usually implanted by neurointerventional methods for aneurysm treatment (especially the treatment of cerebral aneurysms). The dense mesh stent can significantly reduce the blood flow rate and flow entering the aneurysm by using the principle of hemodynamics, gradually forming a thrombus in the aneurysm, and then eliminating the thrombus through blood metabolism to reconstruct the blood vessels at the lesion. It has many advantages such as high safety, wide range of indications, and convenient operation. However, after the dense mesh stent is implanted as a foreign body in the artery, it will cause an immune response in the body's related tissues. The most unfavorable thing for the treatment of aneurysms is the acute coagulation reaction, which will form thrombi or even blood clots on the surface and inside of the dense mesh stent, and then block the dense mesh stent, affecting the blood supply to the brain and posing the risk of cerebral infarction. The current main practice is for patients to take dual-antibody drugs after surgery, which not only increases the occurrence of postoperative complications, but also puts a huge psychological pressure and economic burden on patients.

[0003] Therefore, the research focus is to modify the surface function of dense mesh stents to improve their anticoagulant properties and reduce the risk of thrombosis. However, the dense mesh stents in the existing technology at least have the problem of poor anticoagulant effect.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] One of the purposes of the present invention is to provide a method for preparing a stent with a modified layer, so as to at least improve the anticoagulant effect of the stent.

[0006] The second object of the present invention is to provide a stent with a modified layer prepared by the above preparation method.

[0007] A third object of the present invention is to provide a stent with a modified layer containing the above-mentioned implant device.

[0008] This application can be implemented as follows:

[0009] In a first aspect, the present application provides a method for preparing a stent having a modified layer, comprising the following steps:

[0010] The superhydrophilic monomer is sprayed and adsorbed onto the stent matrix to which the transition stage reactant is attached while being ionized, and dried for the first time to obtain a stent primary product with a modified layer;

[0011] The initial scaffold product and the transition stage reactant solution are mixed and grafted for the second time, and then the superhydrophilic monomer solution is added to the mixed system of the initial scaffold product and the transition stage reactant solution by dropwise addition to react, and dried for the second time to obtain a scaffold with a modified layer.

[0012] In an optional embodiment, the spraying power is 15-25 W, and the spraying time is 20-40 s.

[0013] In an optional embodiment, the super hydrophilic monomer solution is added at a dripping speed of 2.5-3.5 mL / min.

[0014] In an optional embodiment, before the super-hydrophilic monomer solution is added dropwise, the process also includes removing water generated during the mixing process of the initial scaffold product and the transition stage reactant solution.

[0015] In an optional embodiment, a molecular sieve is used to remove water generated during the mixing process of the initial scaffold product and the transition stage reactant solution.

[0016] In an alternative embodiment, the molecular sieve is a 3A molecular sieve.

[0017] In an alternative embodiment, the first drying and the second drying are independently performed at 50-80°C.

[0018] In an optional embodiment, the material of the stent matrix includes polylactic acid, polycaprolactone, nickel titanium, cobalt chromium, 304 stainless steel or 316 stainless steel.

[0019] In an optional embodiment, the transition zone reactant includes at least one of amino acid, methyl aminochlorobenzoate, aminopropyltriethoxysilane, semicarbazide, aminocaproic acid, aminopyrine and aminosulfur.

[0020] In alternative embodiments, the amino acids include at least one of glycine, alanine, leucine, asparagine, glutamic acid, tyrosine, serine, arginine, lysine, isoleucine, methionine, proline, and tryptophan.

[0021] In an alternative embodiment, the superhydrophilic monomer comprises phosphorylcholine and polyethylene glycol.

[0022] In an optional embodiment, the superhydrophilic monomer further includes at least one of hyaluronic acid, urea, alginate and ammonium ethophosphate.

[0023] In a second aspect, the present application provides a stent having a modified layer, which is prepared by the preparation method of any one of the aforementioned embodiments.

[0024] In a third aspect, the present application provides an implant device comprising the stent with a modified layer according to the aforementioned embodiment.

[0025] In an alternative embodiment, the implantable device is an implantable device for treating cerebral vascular aneurysms.

[0026] The beneficial effects of this application include:

[0027] The present application adopts a method of spraying and adsorbing superhydrophilic monomers onto a stent grafted with a transition section reactant while ionizing, so that the transition section reactant reacts with the superhydrophilic monomer and forms a firm coating (modification layer) on the surface of the metal stent substrate.

[0028] Compared with the existing blood flow guiding device which uses chemical grafting process by immersion, this method greatly improves the firmness of the coating through the adsorption of atomic bond energy after electrolysis, prolongs the effective action time of the modification layer, and thus improves the anti-coagulation effect of the stent.

[0029] After the second grafting, the super-hydrophilic monomer solution is added to the mixed system of the initial stent and the second transition section reactant solution by dripping, so that the transition section reactant after the second grafting can react chemically with the newly added super-hydrophilic monomer evenly and fully, further improving the uniformity, flatness and firmness of the coating, and is more conducive to improving the anti-coagulation effect of the stent. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0031] Figure 1 This is the UP dripping test data result diagram in Test Example 1;

[0032] Figure 2 This is the test result diagram of the UP dripping experiment in Test Example 1;

[0033] Figure 3 This is a screenshot of the half-body test in Test Example 2;

[0034] Figure 4 is a scanning electron microscope image of each bracket after the test in Test Example 2;

[0035] Figure 5 This is the fluorescence staining result diagram in Experimental Example 3;

[0036] Figure 6 is a scanning electron microscope image of each stent after the coagulation test in Experimental Example 4;

[0037] Figure 7 This is the result diagram of each bracket after the fatigue acceleration test in Test Example 5. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0039] The following is a detailed description of the stent with a modified layer provided in the present application, its preparation method, and its implantation device.

[0040] The inventor has proposed that: in the prior art, the coating obtained by chemical grafting by immersion has poor firmness with the stent, and is easy to fall off and peel off, resulting in a short anticoagulant effect time of the modified stent, and cannot achieve a good anticoagulant effect. Based on this, the present application proposes a method for preparing a stent with a modified layer, comprising the following steps:

[0041] The superhydrophilic monomer is sprayed and adsorbed onto the stent matrix to which the transition stage reactant is attached while being ionized, and dried for the first time to obtain a stent primary product with a modified layer;

[0042] The initial scaffold product and the transition stage reactant solution are mixed and grafted for the second time, and then the superhydrophilic monomer solution is added to the mixed system of the initial scaffold product and the transition stage reactant solution by dropwise addition to react, and dried for the second time to obtain a scaffold with a modified layer.

[0043] For reference, "the super-hydrophilic monomer is sprayed and adsorbed onto the support grafted with the transition section reactant while being ionized" can be carried out by using ultrasonic charged particle spray atomization equipment.

[0044] As an option, the spraying power can be 15-25W, such as 15W, 16W, 17W, 18W, 19W, 20W, 21W, 22W, 23W, 24W or 25W, or any other value within the range of 15-25W.

[0045] The spraying time may be illustratively 20-40 seconds, such as 20 seconds, 25 seconds, 30 seconds, 35 seconds or 40 seconds, etc., or may be any other value within the range of 20-40 seconds.

[0046] It should be noted that if the spraying time is too short, the coating thickness will be thinner and will not improve the coating firmness. If the spraying time is too long, the coating will be too thick, causing the stress points of the coating to concentrate when the stent is bent, resulting in coating damage, fracture or peeling.

[0047] Specifically, the preparation process of the initial stent can refer to:

[0048] Add the transition stage reactant to the first solvent, and then add the stent matrix after the transition stage reactant is dissolved, so that the stent matrix is ​​completely immersed in the first solvent in which the transition stage reactant is dissolved, and soak for 5-10 minutes, then take out the wetted stent and clamp it on the charged fixture. For the sake of distinction, the mixed solution of the transition stage reactant and the first solvent in this process is called the "first transition stage reactant solution".

[0049] The super-hydrophilic monomer is added to the second solvent, and after the super-hydrophilic monomer is dissolved, it is transferred to the ultrasonic charged particle spraying atomization device. For the convenience of distinction, the mixed liquid of the super-hydrophilic monomer and the second solvent in this process is called the "first super-hydrophilic monomer solution".

[0050] Subsequently, the ultrasonic charged particle spray atomization equipment is turned on to first atomize the first super-hydrophilic monomer solution into fine particles, and then evenly coated on the surface of the stent moistened with the first transition stage reactant solution through a carrier gas. The transition stage reactant reacts with the super-hydrophilic monomer and forms a firm coating (modification layer) on the surface of the metal stent substrate.

[0051] For reference, the mass ratio of the transition section reactant to the first solvent can be 1-10:50, such as 1:50, 2:50, 3:50, 4:50, 5:50, 6:50, 7:50, 8:50, 9:50 or 10:50, or any other value within the range of 1-10:50.

[0052] The mass ratio of the super hydrophilic monomer to the second solvent can be 0.1-5:100, such as 0.1:100, 0.5:100, 1:100, 1.5:100, 2:100, 2.5:100, 3:100, 3.5:100, 4:100, 4.5:100 or 5:100, or any other value within the range of 0.1-5:100.

[0053] As an option, the material of the stent matrix used in the present application may illustratively but not limitatively include polylactic acid, polycaprolactone, nickel titanium, cobalt chromium, 304 stainless steel or 316 stainless steel, etc.

[0054] The transition stage reactant may illustratively but not limitatively include at least one of amino acid, methyl aminochlorobenzoate, aminopropyltriethoxysilane, semicarbazide, aminocaproic acid, aminopyrine and aminosulfur.

[0055] Among them, the amino acids preferably include at least one of glycine, alanine, leucine, asparagine, glutamic acid, tyrosine, serine, arginine, lysine, isoleucine, methionine, proline and tryptophan.

[0056] The superhydrophilic monomer may illustratively but not limitatively include phosphorylcholine and polyethylene glycol, and may further include at least one of hyaluronic acid, urea, alginic acid and ammonium ethophosphate.

[0057] Accordingly, the first solvent and the second solvent are independently selected from at least one of water, ethanol, propanol, butanol, acetone, ethyl acetate, mannitol, tetrahydrofuran, cyclohexane, dimethyl sulfoxide and formamide according to the solubility characteristics of the transition section reactant and the super hydrophilic monomer to be dissolved. That is, the selected first solvent needs to be able to dissolve the transition section reactant, and the selected second solvent needs to be able to dissolve the super hydrophilic monomer.

[0058] Compared with the existing blood flow guidance device chemical grafting process by immersion, the above-mentioned method of spraying and adsorbing the superhydrophilic monomer onto the stent attached with the transition section reactant while ionizing it greatly improves the firmness of the coating through the adsorption of atomic bond energy after electrolysis, and also effectively improves the hydrophilicity and biocompatibility of the stent.

[0059] For reference, the first drying can be carried out at 50-80°C. The specific drying temperature can be 50°C, 55°C, 60°C, 65°C, 70°C, 75°C or 80°C, etc., or any other value within the range of 50-80°C.

[0060] Specifically, the first drying can be carried out in an oven, and the baking time can be, for example, 100-150 min, such as 100 min, 110 min, 120 min, 130 min, 140 min or 150 min, or any other value within the range of 100-150 min.

[0061] The inventors propose that: the coating of the initial stent obtained by the above-mentioned spraying method has a material at the micron level and the coating has poor flatness.

[0062] Based on this, after obtaining the initial scaffold, the present application also mixes it with the transition section reactant solution and performs a second grafting, and then reacts with the super-hydrophilic monomer solution.

[0063] For the sake of distinction, the transition stage reactant solution used to mix with the primary scaffold during the second grafting process is referred to as the "second transition stage reactant solution", and the super-hydrophilic monomer solution involved thereafter is referred to as the "second super-hydrophilic monomer solution". The transition stage reactant, super-hydrophilic monomer, first solvent and second solvent involved in the "second transition stage reactant solution" and the "second super-hydrophilic monomer solution" can be selected from the corresponding substances mentioned in the above content.

[0064] Preferably, after the second grafting, the super-hydrophilic monomer solution is added to the mixed system of the initial scaffold product and the second transition stage reactant solution by dropwise addition. The dropwise addition can be performed by a peristaltic pump.

[0065] For reference, the dripping speed of the superhydrophilic monomer solution can be illustratively 2.5-3.5 mL / min, such as 2.5 mL / min, 2.8 mL / min, 3 mL / min, 3.2 mL / min or 3.5 mL / min, etc., or any other value within the range of 2.5-3.5 mL / min.

[0066] It should be noted that if the dripping acceleration is too fast, it is easy to cause a violent reaction, resulting in poor uniformity of the coating. In the present application, by dripping the second super-hydrophilic monomer solution at the above dripping acceleration, the transition section reactants after the second grafting can react evenly and fully with the newly added super-hydrophilic monomer, further improving the uniformity, flatness and firmness of the coating.

[0067] In some preferred embodiments, before the super-hydrophilic monomer solution is added dropwise, the method further includes removing water generated during the mixing process of the initial scaffold product and the transition stage reactant solution.

[0068] For reference, molecular sieves (such as 3A molecular sieves) can be used to remove water in the above process.

[0069] By adding molecular sieves to adsorb the moisture produced during the reaction, side reactions can be effectively reduced, which is conducive to obtaining a coating with better performance.

[0070] For reference, the second drying can also be carried out at 50-80°C. The specific drying temperature can be 50°C, 55°C, 60°C, 65°C, 70°C, 75°C or 80°C, etc., or any other value within the range of 50-80°C.

[0071] Specifically, the second drying can be performed in an oven until the water content in the stent product does not exceed 1 wt %.

[0072] It should be noted that the reaction principles not described in detail in this application can be referred to the relevant prior art and will not be elaborated here.

[0073] Accordingly, the present application also provides a stent with a modified layer, which is prepared by the above preparation method. The stent with the modified layer has good hydrophilicity, biocompatibility, anticoagulant property and coating firmness.

[0074] The above-mentioned stent with a modified layer can be used to prepare aneurysm-related implantable devices, which can improve the acute anticoagulation function after implantation in the body and reduce the risk of postoperative thrombosis and cerebral ischemia.

[0075] In addition, the present application also provides an implant device, which contains the above-mentioned stent with a modified layer.

[0076] As an example, the implant device may be an implant device for treating cerebral vascular aneurysms.

[0077] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0078] Example 1

[0079] This embodiment provides a stent with a modified layer, and the preparation method thereof is as follows:

[0080] ① Weigh 0.5 g of arginine and add it to 25 g of ethanol aqueous solution (containing 10 g of ethanol) to obtain the first transition stage reactant solution after dissolution; completely immerse the 304 stainless steel bracket substrate in the first transition stage reactant solution for 10 minutes, take out the wetted 304 stainless steel bracket substrate and clamp it on a charged fixture.

[0081] ② Weigh 0.5 g of phosphorylcholine, add it to 100 g of formamide (the second solvent), and dissolve it to obtain a first super-hydrophilic monomer solution; add the first super-hydrophilic monomer solution into an ultrasonic charged particle spraying atomization device.

[0082] ③ Turn on the ultrasonic charged particle spray atomization equipment, and spray and adsorb the superhydrophilic monomer onto the charged wetted stent matrix while ionizing it in a Class 100 clean area.

[0083] The spraying power during the spray atomization process is 20W and the spraying time is 30s.

[0084] ④ Then take out the stent matrix obtained in ③ above, put it into an oven at 80°C and bake it for 2 hours to obtain a primary stent with a modified layer.

[0085] ⑤ After taking out the scaffold product with the modified layer, put it into the second transition stage reactant solution obtained by mixing arginine and ethanol aqueous solution, and add 3A molecular sieve to remove the water generated during the mixing process of the scaffold product and the second transition stage reactant solution, and then use a peristaltic pump to drop 100mL of the second super hydrophilic monomer solution into the mixed system of the above scaffold product and the second transition stage reactant solution within 30 minutes.

[0086] The second transition stage reactant solution has the same composition as the first transition stage reactant solution, and the second super-hydrophilic monomer solution has the same composition as the first super-hydrophilic monomer solution.

[0087] ⑥ After the dropwise addition is completed, dry in an oven at 80°C until the water content of the stent product does not exceed 1wt%.

[0088] Example 2

[0089] This embodiment provides a stent with a modified layer, and the preparation method thereof is as follows:

[0090] ① Weigh 1g of aminopropyltriethoxysilane and add it to 50g of propanol to obtain the first transition stage reactant solution after dissolution; completely immerse the cobalt-chromium bracket substrate in the first transition stage reactant solution for 5 minutes, take out the wetted cobalt-chromium bracket substrate and clamp it on a charged fixture.

[0091] ② Weigh 2 g of alginate and 0.5 g of phosphorylcholine, add them to 100 g of formamide (the second solvent), and dissolve them to obtain a first super-hydrophilic monomer solution; add the first super-hydrophilic monomer solution to an ultrasonic charged particle spray atomization device.

[0092] ③ Turn on the ultrasonic charged particle spray atomization equipment, and spray and adsorb the superhydrophilic monomer onto the charged wetted stent matrix while ionizing it in a Class 100 clean area.

[0093] The spraying power during the spray atomization process is 15W, and the spraying time is 40s.

[0094] ④ Then take out the stent matrix obtained in ③ above, put it into a 60°C oven and bake it for 150 minutes to obtain a primary stent with a modified layer.

[0095] ⑤ After taking out the initial product of the scaffold with the modified layer, put it into the second transition stage reactant solution obtained by mixing aminopropyltriethoxysilane and propanol, and add 3A molecular sieve to remove the water produced during the mixing process of the initial product of the scaffold and the second transition stage reactant solution, and then use a peristaltic pump to drop 75mL of the second super hydrophilic monomer solution into the mixed system of the above initial product of the scaffold and the second transition stage reactant solution within 30 minutes.

[0096] The second transition stage reactant solution has the same composition as the first transition stage reactant solution, and the second super-hydrophilic monomer solution has the same composition as the first super-hydrophilic monomer solution.

[0097] ⑥ After the dropwise addition is completed, dry in an oven at 60°C until the water content of the stent product does not exceed 1wt%.

[0098] Example 3

[0099] This embodiment provides a stent with a modified layer, and the preparation method thereof is as follows:

[0100] ① Weigh 0.5g of glutamic acid and add it to 2.5g of ethanol aqueous solution (containing 0.5g of ethanol) to obtain the first transition stage reactant solution after dissolution; completely immerse the nickel-titanium stent matrix in the first transition stage reactant solution for 7.5min, take out the wetted nickel-titanium stent matrix and clamp it on a charged fixture.

[0101] ② Weigh 1 g of polyethylene glycol and 0.5 g of phosphorylcholine, add them to 1500 g of formamide (the second solvent), and dissolve them to obtain a first super-hydrophilic monomer solution; add the first super-hydrophilic monomer solution to an ultrasonic charged particle spray atomization device.

[0102] ③ Turn on the ultrasonic charged particle spray atomization equipment, and spray and adsorb the superhydrophilic monomer onto the charged wetted stent matrix while ionizing it in a Class 100 clean area.

[0103] The spraying power during the spray atomization process is 25W, and the spraying time is 20s.

[0104] ④ Then take out the stent matrix obtained in ③ above, put it into a 50°C oven and bake it for 150 minutes to obtain a primary stent with a modified layer.

[0105] ⑤ After taking out the initial product of the scaffold with the modified layer, put it into the second transition stage reactant solution obtained by mixing glutamic acid and ethanol aqueous solution, and add 3A molecular sieve to remove the water generated during the mixing process of the initial product of the scaffold and the second transition stage reactant solution, and then use a peristaltic pump to drop 105mL of the second super hydrophilic monomer solution into the mixed system of the above initial product of the scaffold and the second transition stage reactant solution within 30 minutes.

[0106] The second transition stage reactant solution has the same composition as the first transition stage reactant solution, and the second super-hydrophilic monomer solution has the same composition as the first super-hydrophilic monomer solution.

[0107] ⑥ After the dropwise addition is completed, dry in an oven at 50°C until the water content of the stent product does not exceed 1wt%.

[0108] Test Example 1

[0109] Hydrophilicity test

[0110] The stent with the modified layer prepared in Example 1 was used as the test sample, the Pipeline Flex Embolization Device with Shield Technology containing silane and phosphorylcholine produced by Medtronic was used as the pipeline control group, and the 304 stainless steel stent matrix same as that in Example 1 was used as the bare stent control group.

[0111] The UP dripping experiment was performed on the above test group, pipeline control group and bare stent control group. The results are as follows: Figure 1 and Figure 2 shown.

[0112] Depend on Figure 1 and Figure 2It can be seen that the hydrophilic angle of the bare stent is about 75°, which has the largest hydrophilic angle among the three groups, indicating that its hydrophilicity is the worst; followed by the Pipeline sample (whose hydrophilic angle is about 24°); the test sample has the smallest hydrophilic angle (about 6°), indicating that the stent with a modified layer prepared in Example 1 of the present application has significantly better hydrophilicity than the bare stent and the Pipeline sample.

[0113] Test Example 2

[0114] Rabbit in vitro animal test (also known as "half-body test")

[0115] The stent with the modified layer prepared in Example 1 was used as the test sample, the Pipeline Flex Embolization Device with Shield Technology containing silane and phosphorylcholine produced by Medtronic was used as the pipeline control group, and the 304 stainless steel stent matrix same as that in Example 1 was used as the bare stent control group.

[0116] The experimental subjects were 2.5-3kg adult New Zealand white rabbits, and 4 parallel samples were set for each group of samples.

[0117] Experimental consumables: surgical instruments (indwelling needles, microscissors, hemostatic forceps, medical surgical blades, etc.), medical surgical sutures, sterile gloves, laboratory coats, PVC disposable catheters, etc.

[0118] Experimental reagents: pentobarbital, sodium heparin injection, sodium chloride, etc.

[0119] Compared with in vitro experiments, this experiment can more intuitively and systematically reflect the anticoagulant properties of samples, which is conducive to further testing of blood-related properties.

[0120] This experiment uses a rabbit model, and the experimental steps are as follows:

[0121] (1) Select healthy adult New Zealand white rabbits weighing 2.5-3 kg as models, prepare an anesthetic of appropriate concentration, and inject the anesthetic into the rabbit through the ear vein at a ratio of 1 kg to 1 ml. Depilate the rabbit's neck artery and vein;

[0122] (2) Place the stent into the PVC catheter and inject sodium chloride until the catheter is full. Clamp both ends of the catheter with hemostatic forceps for later use.

[0123] (3) Use a scalpel to cut open the skin on the rabbit's neck, peel off the muscle tissue layer by layer, and carefully separate the arteries and veins;

[0124] (4) Insert the indwelling needle into the stripped artery and vein, and then connect the two ports of the indwelling needle to the PVC catheter containing the sample to form a closed blood circulation loop with the rabbit's blood vessels. Remove the hemostatic clamps at both ends of the catheter and start timing, continuously observing the changes in blood color in the PVC catheter, and check the flow every 10 minutes to observe whether the catheter is blocked.

[0125] (5) 30 minutes after the start of the experiment, blood circulation was stopped, the catheter device was removed, and the sample was cleaned with physiological saline. The cleaned sample was placed under a white light board to photograph its cross section, and the blockage rate of the stent before and after modification and the weight of the thrombus were calculated. The sample was fixed with 2.5% glutaraldehyde, dehydrated and dealcoholized after 4 hours, and then sprayed with gold for scanning electron microscopy observation.

[0126] The results are as follows Figure 3 and Figure 4 As shown, Figure 3 Screenshot of the half-body test. Figure 4 This is a scanning electron microscope image.

[0127] Depend on Figure 3 It can be seen that arterial blood is drawn out through a heparin-coated catheter, a stent is placed inside the catheter, and the blood flows through the stent and then flows back into the rabbit's body, forming a closed loop of artificial arterial drainage.

[0128] Depend on Figure 4 It can be seen that: the bare stent surface has serious material adhesion, indicating that its anti-coagulation performance is the worst; followed by the Pipeline sample, which also has more material adhered to its surface; the test sample has the least material adhered to the surface, indicating that the stent with a modified layer prepared in Example 1 of the present application has significantly better anti-coagulation performance than the bare stent and the Pipeline sample.

[0129] Test Example 3

[0130] Platelet Adhesion and Activation Test Results

[0131] The stent with the modified layer prepared in Example 1 was used as the test sample, the Pipeline Flex Embolization Device with Shield Technology containing silane and phosphorylcholine produced by Medtronic was used as the pipeline control group, and the 304 stainless steel stent matrix same as that in Example 1 was used as the bare stent control group.

[0132] The experimental steps are as follows:

[0133] (1) The blood used in this experiment was donated by anonymous volunteers. Fresh blood was mixed with 3.8% sodium citrate at a ratio of 10:1, centrifuged for 15 min at 1500 rpm, and the supernatant was taken as the plate-rich plasma (PRP);

[0134] (2) Add the prepared samples to a 24-well plate, drip 100 μL of the plate-enriched slurry onto the surface of each sample, and incubate in a 37°C constant temperature incubator for 1 h;

[0135] (3) The incubated samples were removed and washed three times with 0.9% sodium chloride and fixed with 2.5% glutaraldehyde for 4 h;

[0136] In this experiment, immunofluorescence staining and scanning electron microscopy were used to observe the adhesion morphology and activation of platelets. The immunofluorescence staining steps were as follows:

[0137] (1) Wash the fixed samples three times with 0.9% sodium chloride;

[0138] (2) Add 70 μL of rhodamine-phalloidin solution to the surface of each sample and place it in a dark place for 15 min;

[0139] (3) Wash the stained samples three times with 0.9% sodium chloride and blow dry, then observe under a fluorescence microscope.

[0140] The steps for scanning and observing platelets in this experiment are as follows:

[0141] (1) Dehydration of the above samples: Place the samples in 50%, 75%, 90% and 100% alcohol solutions in sequence, each for 15 min;

[0142] (2) Dealcoholization treatment: The sample was placed in 50%, 75%, 90% and 100% isoamyl acetate solutions, respectively, for 15 min each time;

[0143] (3) Critical point drying, gold spraying and observation by scanning electron microscope.

[0144] Fluorescence staining results Figure 5 As shown by Figure 5 It can be seen that: more platelets adhere to the surface of the bare stent, indicating that its anti-coagulation performance is the worst; followed by the Pipeline sample; the test sample has the least platelets adhered to the surface, indicating that the stent with a modified layer prepared in Example 1 of the present application has significantly better anti-coagulation performance than the bare stent and the Pipeline sample.

[0145] Test Example 4

[0146] SEM scaffold screenshot after coagulation test in Example 1

[0147] The SEM screenshots of the stent with a modified layer and the pipeline control group prepared in Example 1 of the present application after the above coagulation test are as follows: Figure 6 shown.

[0148] Depend on Figure 6 It can be seen that the surface flatness of the stent in the pipeline control group is poor, while the surface of the stent with the modified layer prepared in Example 1 of the present application is smooth and flat.

[0149] Test Example 5

[0150] Coating fastness

[0151] The above test samples, pipeline control group and bare stent control group were subjected to stent fatigue accelerated testing equivalent to 24 months. The results are as follows Figure 7 shown.

[0152] Depend on Figure 7 It can be seen that the bare stent is severely broken; the coating surface of the pipeline control group is slightly peeled off; and the coating on the surface of the test sample is evenly distributed without any signs of peeling or breakage.

[0153] As mentioned above, the stent with a modified layer provided in Example 1 of the present application is superior to the pipeline group and the bare stent in terms of biocompatibility, anticoagulability, hydrophilicity and firmness.

[0154] In summary, the present application uses a method of spraying and adsorbing super-hydrophilic monomers onto the stent grafted with the transition section reactant while ionizing, which is compared with the existing blood flow guidance device that performs chemical grafting by immersion. The adsorption of atomic bond energy after electrolysis greatly improves the firmness of the coating, and also effectively improves the hydrophilicity and biocompatibility of the stent. After the electrolysis adsorption step, the uniform chemical reaction method of dripping with a peristaltic pump further improves the uniformity of the surface coating, and the water generated during the molecular sieve adsorption reaction is added during the reaction process, reducing side reactions, so that the coating has excellent comprehensive performance.

[0155] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing a stent with a modified layer, characterized in that: The following steps are involved: Add the transition stage reactant into the first solvent, add the support matrix after the transition stage reactant is dissolved, and completely immerse the support matrix in the first solvent containing the transition stage reactant for 5-10 minutes, then take out the wetted support matrix and clamp it on a charged fixture; adding a super-hydrophilic monomer into a second solvent, and transferring the super-hydrophilic monomer into an ultrasonic charged particle spraying atomization device after it is dissolved; The ultrasonic charged particle spraying atomization equipment is turned on to spray and adsorb the superhydrophilic monomer onto the charged wetted stent substrate attached with the transition section reactant while ionizing, and then dried for the first time to obtain a stent primary product with a modified layer; The initial scaffold product is mixed with the transition stage reactant solution and grafted for a second time, and then the superhydrophilic monomer solution is added to the mixed system of the initial scaffold product and the transition stage reactant solution by dropwise addition to react, and dried for a second time to obtain a scaffold with a modified layer; The spraying power is 15-25W and the spraying time is 20-40s; The super-hydrophilic monomer solution is added at a rate of 2.5-3.5 mL / min; The material of the stent matrix is ​​selected from polylactic acid, polycaprolactone, nickel titanium, cobalt chromium, 304 stainless steel or 316 stainless steel; The transition section reactant is selected from at least one of amino acids, methyl aminochlorobenzoate, aminopropyltriethoxysilane, semicarbazide, aminocaproic acid, aminopyrine and aminosulfur; The superhydrophilic monomer includes phosphorylcholine and polyethylene glycol; Before the super-hydrophilic monomer solution is added dropwise, the method further includes removing water generated during the mixing process of the primary scaffold product and the transition section reactant solution.

2. The preparation method according to claim 1, characterized in that: Molecular sieves are used to remove water generated during the mixing process of the primary scaffold product and the transition stage reactant solution.

3. The preparation method according to claim 2, characterized in that: The molecular sieve is 3A molecular sieve.

4. The preparation method according to claim 1, characterized in that: The first drying and the second drying are independently carried out at 50-80°C.

5. The preparation method according to any one of claims 1 to 4, characterized in that: The amino acids include at least one of glycine, alanine, leucine, asparagine, glutamic acid, tyrosine, serine, arginine, lysine, isoleucine, methionine, proline and tryptophan.

6. The preparation method according to any one of claims 1 to 4, characterized in that: The super-hydrophilic monomer further comprises at least one of hyaluronic acid, urea, alginate and ammonium ethylphosphate.

7. A stent with a modified layer, characterized in that: The invention is prepared by the preparation method according to any one of claims 1 to 6.

8. An implant device, characterized in that: A stent with a modified layer as claimed in claim 7.

9. The implant device according to claim 8, characterized in that The implantable device is an implantable device for treating cerebral vascular aneurysms.

Citation Information

Patent Citations

  • Hydrophilic coat solution applied to surface of medicinal instrument and preparation method thereof

    CN101812265A

  • Anti-thrombogenic medical devices and methods

    CN105744965A

  • Method for acquiring active surface layer generating active free radical and group on surface of inorganic medical equipment

    CN110180037A

  • Hydrophilic, antibacterial and anti-protein-adhesion silicone rubber and preparation method thereof

    CN112745508A

  • Application of non-release type anti-microbial adhesion coating in antibacterial medical instrument

    CN113797399A